1310.4000 9.60 (0.74%)
NSE Sep 16, 2025 15:31 PM
Volume: 1.0M
 

BOB Capital Markets Ltd.
Dr Reddy's (DRRD) has announced a key settlement of the patent litigation with Celgene for US Revlimid (lenalidomide capsules) used to treat multiple myeloma.
Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
More from Dr. Reddy's Laboratories Ltd.
Recommended